RxDoctor Payments Data

Gary Spektor, MD

Cardiovascular Disease · Brooklyn, NYNPI 1043275092

Payments from drug & device makers

$3,519in general payments, 2019–2025

Across 165 payments — averaging $21.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$602
  • Amarin Pharma, Inc.$578
  • Pfizer$331
  • Johnson & Johnson$256
  • Esperion Therapeutics, Inc.$255
  • Kowa Pharmaceuticals America, Inc.$231
  • plus $1K from 17 others

What the payments were for

  • Food & beverage$3,519100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,519 in reported general payments places this provider in the 60th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$538,340
Medicare patients
304
Services billed
3,529

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban449$380,320
VascepaIcosapent Ethyl488$208,942
EntrestoSacubitril/Valsartan202$181,183
XareltoRivaroxaban133$127,270
LivaloPitavastatin Calcium68$31,297
Icosapent Ethyl151$26,903
Ranolazine ErRanolazine425$26,767
Pitavastatin Calcium85$23,090
Nebivolol Hcl236$14,121
NexletolBempedoic Acid15$11,771
Isosorbide Mononitrate ErIsosorbide Mononitrate682$11,115
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide142$9,874
Metoprolol Succinate491$9,130
Rosuvastatin Calcium649$6,727
Benicar HctOlmesartan/Hydrochlorothiazide21$5,566

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$331$380,320449 claims
NovartisEntresto$602$181,183202 claims
Johnson & JohnsonXarelto$256$127,270133 claims
Kowa Pharmaceuticals America, Inc.Livalo, Bystolic$231$36,25080 claims
Esperion Therapeutics, Inc.Nexletol$255$11,77115 claims
Arbor Pharmaceuticals, Inc.Edarbyclor$28$5,27714 claims
AstraZenecaCrestor$114$5,05214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →